Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19: A Systematic Review

H. Akbari
{"title":"Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19: A Systematic Review","authors":"H. Akbari","doi":"10.22037/AMLS.V6.32399","DOIUrl":null,"url":null,"abstract":"COVID-19 pneumonia signs and symptoms are not specific and it may be similar to other cases of pneumonia caused by other microorganisms such as Mycoplasma pneumonia. This study aimed to investigate the prevalence of M. pneumonia co-infection among patients with COVID-19 by a systematic review and meta-analysis. \nTwo authors performed the search process independently in Scopus, Web of sciences, and PubMed for studies reporting COVID-19-associated Mycoplasma pneumonia co-infections published in the English language from December 2019 to 1st June 2020. The MeSH terms used in the present review were; “COVID-19”, “co-infection”, “secondary infection”, “2019 novel coronavirus”, “2019-nCoV”, “COVID-19 virus”, “coronavirus disease 2019 virus”, “Mycoplasma pneumoniae”, “M. pneumoniae”, “prevalence”, and “respiratory pathogens”. Data analyzed using Comprehensive Meta-analysis (CMA) software. Heterogeneity among included studies was checked by I2 statistic and the Q2 test. M. pneumonia co-infection was varied between 1 and 40.6% in the included studies. The combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17% (95% CI: 7.4–34.3). \nOverall, our systematic review and meta-analysis showed a quite high co-infection of M. pneumonia in patients with COVID-19 infection, therefore, routine diagnostic tests are recommended for respiratory pathogens like M. pneumonia, because on-time treatment has a beneficial effect on patient survival. Also, an increasing number of cases of asymptomatic COVID-19 infection, the differentiation and diagnosis of pneumonia caused by COVID-19 from non-COVID-19 pneumonia be considered. It helps avoid unnecessary quarantine and waste of medical resources. \n*Corresponding Author: Hakimeh Akbari; Email: akbarih@gerums.ac.ir \nPlease cite this article as: Akbari H. Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19; a systematic review. Arch Med Lab Sci. 2020;6:e3. https://doi.org/10.22037/amls.v6.32399","PeriodicalId":18401,"journal":{"name":"Medical laboratory sciences","volume":"52 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical laboratory sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22037/AMLS.V6.32399","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

COVID-19 pneumonia signs and symptoms are not specific and it may be similar to other cases of pneumonia caused by other microorganisms such as Mycoplasma pneumonia. This study aimed to investigate the prevalence of M. pneumonia co-infection among patients with COVID-19 by a systematic review and meta-analysis. Two authors performed the search process independently in Scopus, Web of sciences, and PubMed for studies reporting COVID-19-associated Mycoplasma pneumonia co-infections published in the English language from December 2019 to 1st June 2020. The MeSH terms used in the present review were; “COVID-19”, “co-infection”, “secondary infection”, “2019 novel coronavirus”, “2019-nCoV”, “COVID-19 virus”, “coronavirus disease 2019 virus”, “Mycoplasma pneumoniae”, “M. pneumoniae”, “prevalence”, and “respiratory pathogens”. Data analyzed using Comprehensive Meta-analysis (CMA) software. Heterogeneity among included studies was checked by I2 statistic and the Q2 test. M. pneumonia co-infection was varied between 1 and 40.6% in the included studies. The combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17% (95% CI: 7.4–34.3). Overall, our systematic review and meta-analysis showed a quite high co-infection of M. pneumonia in patients with COVID-19 infection, therefore, routine diagnostic tests are recommended for respiratory pathogens like M. pneumonia, because on-time treatment has a beneficial effect on patient survival. Also, an increasing number of cases of asymptomatic COVID-19 infection, the differentiation and diagnosis of pneumonia caused by COVID-19 from non-COVID-19 pneumonia be considered. It helps avoid unnecessary quarantine and waste of medical resources. *Corresponding Author: Hakimeh Akbari; Email: akbarih@gerums.ac.ir Please cite this article as: Akbari H. Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19; a systematic review. Arch Med Lab Sci. 2020;6:e3. https://doi.org/10.22037/amls.v6.32399
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19患者肺炎支原体合并感染的患病率:一项系统综述
COVID-19肺炎的体征和症状不具有特异性,可能与其他微生物(如肺炎支原体)引起的其他肺炎病例相似。本研究旨在通过系统回顾和荟萃分析调查COVID-19患者中肺炎支原体合并感染的患病率。两位作者在Scopus、Web of sciences和PubMed中独立进行了搜索过程,检索了2019年12月至2020年6月1日以英语发表的报告covid -19相关支原体肺炎合并感染的研究。本审查中使用的MeSH术语是;“COVID-19”、“合并感染”、“继发感染”、“2019新型冠状病毒”、“2019- ncov”、“COVID-19病毒”、“冠状病毒病2019病毒”、“肺炎支原体”、“M。“肺炎”、“患病率”和“呼吸道病原体”。数据分析采用综合元分析(CMA)软件。采用I2统计量和Q2检验检验纳入研究间的异质性。在纳入的研究中,肺炎支原体合并感染的发生率在1%至40.6%之间。COVID-19患者中合并肺炎支原体感染的总患病率为17% (95% CI: 7.4-34.3)。总体而言,我们的系统回顾和荟萃分析显示,COVID-19感染患者的肺炎支原体合并感染率相当高,因此,建议对肺炎支原体等呼吸道病原体进行常规诊断检查,因为及时治疗对患者的生存有有益的影响。同时,随着新冠肺炎无症状感染者的增多,需要考虑新冠肺炎与非新冠肺炎的鉴别诊断。这有助于避免不必要的隔离和医疗资源的浪费。*通讯作者:Hakimeh Akbari;Akbari H. COVID-19患者肺炎支原体合并感染的患病率;系统回顾。中华医学杂志,2020;6:3。https://doi.org/10.22037/amls.v6.32399
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Molecular Typing of Uropathogenic Escherichia coli Strains Isolated from Patients in Gorgan by Random Amplified Polymorphic DNA-PCR (RAPD-PCR) Formulating a New Pharmaceutical Drug; Acetaminophen Tablet Containing N-acetyl Cysteine, To Alleviate the Severity of Liver Damage in Rats: Phase I, Animal Study The Expression Level of CCDC26 and FOXCUT Genes in Acute Lymphoblastic Leukemia A Review of SARS-CoV-2 Genetic and Structure: Hot Cellular Targets for Virus Entry: No Evidence of Hepatitis C Virus Infection in Individuals with Cardiovascular Disease in Mashhad
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1